Fulgent Genetics ROA 2015-2025 | FLGT
Current and historical return on assets (ROA) values for Fulgent Genetics (FLGT) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Fulgent Genetics ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2025-03-31 | $-0.04B | $1.21B | -3.43% |
| 2024-12-31 | $-0.04B | $1.22B | -3.50% |
| 2024-09-30 | $-0.17B | $1.23B | -13.38% |
| 2024-06-30 | $-0.16B | $1.23B | -12.90% |
| 2024-03-31 | $-0.17B | $1.23B | -12.75% |
| 2023-12-31 | $-0.17B | $1.24B | -12.54% |
| 2023-09-30 | $-0.06B | $1.36B | -4.60% |
| 2023-06-30 | $-0.05B | $1.36B | -3.48% |
| 2023-03-31 | $-0.03B | $1.38B | -1.78% |
| 2022-12-31 | $0.14B | $1.39B | 10.07% |
| 2022-09-30 | $0.27B | $1.41B | 19.38% |
| 2022-06-30 | $0.39B | $1.46B | 29.05% |
| 2022-03-31 | $0.46B | $1.47B | 36.88% |
| 2021-12-31 | $0.51B | $1.28B | 44.83% |
| 2021-09-30 | $0.57B | $1.21B | 57.66% |
| 2021-06-30 | $0.49B | $1.05B | 65.95% |
| 2021-03-31 | $0.42B | $1.00B | 81.68% |
| 2020-12-31 | $0.21B | $0.70B | 75.62% |
| 2020-09-30 | $0.05B | $0.25B | 36.85% |
| 2020-06-30 | $0.00B | $0.10B | 2.39% |
| 2020-03-31 | $0.00B | $0.09B | -1.36% |
| 2019-12-31 | $0.00B | $0.09B | -1.53% |
| 2019-09-30 | $0.00B | $0.06B | -5.29% |
| 2019-06-30 | $-0.01B | $0.06B | -9.05% |
| 2019-03-31 | $-0.01B | $0.06B | -10.86% |
| 2018-12-31 | $-0.01B | $0.05B | -10.91% |
| 2018-09-30 | $-0.01B | $0.06B | -10.76% |
| 2018-06-30 | $-0.01B | $0.06B | -10.57% |
| 2018-03-31 | $-0.01B | $0.06B | -8.70% |
| 2017-12-31 | $0.00B | $0.06B | -5.13% |
| 2017-09-30 | $0.00B | $0.06B | 0.00% |
| 2017-06-30 | $0.00B | $0.06B | 0.00% |
| 2017-03-31 | $-0.01B | $0.06B | -11.98% |
| 2016-12-31 | $-0.01B | $0.06B | -22.22% |
| 2016-06-30 | $-0.01B | $0.03B | -88.89% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.587B | $0.283B |
| Fulgent Genetics, Inc. provides genetic testing services to physicians with clinically actionable diagnostic information. The company's technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals and medical institutions. Fulgent Genetics is headquartered in Temple City, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $45.084B | 57.36 |
| Doximity (DOCS) | United States | $11.307B | 52.35 |
| Hims & Hers Health (HIMS) | United States | $10.719B | 111.37 |
| Tempus AI (TEM) | United States | $9.847B | 0.00 |
| IRhythm Technologies (IRTC) | United States | $4.340B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $3.842B | 60.03 |
| Hinge Health (HNGE) | United States | $3.717B | 0.00 |
| Privia Health (PRVA) | United States | $2.496B | 170.58 |
| Enovis (ENOV) | United States | $1.944B | 10.84 |
| Phreesia (PHR) | United States | $1.590B | 0.00 |
| 10x Genomics (TXG) | United States | $1.576B | 0.00 |
| Schrodinger (SDGR) | United States | $1.542B | 0.00 |
| Azenta (AZTA) | United States | $1.532B | 71.21 |
| Clover Health Investments (CLOV) | United States | $1.486B | 0.00 |
| Omnicell (OMCL) | United States | $1.344B | 23.71 |
| Evolent Health (EVH) | United States | $1.313B | 111.80 |
| Claritev (CTEV) | United States | $0.761B | 0.00 |
| Veradigm (MDRX) | United States | $0.547B | 0.00 |
| Standard BioTools (LAB) | United States | $0.501B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.448B | 0.00 |
| Talkspace (TALK) | United States | $0.442B | 132.00 |
| Outset Medical (OM) | United States | $0.344B | 0.00 |
| TruBridge (TBRG) | United States | $0.331B | 735.33 |
| Health Catalyst (HCAT) | United States | $0.271B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.258B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.233B | 0.00 |
| CapsoVision (CV) | United States | $0.212B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.161B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.150B | 0.00 |
| American Well (AMWL) | United States | $0.131B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.123B | 0.00 |
| Pulmonx (LUNG) | United States | $0.117B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.103B | 0.00 |
| CareCloud (CCLD) | United States | $0.101B | 3.84 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.082B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.068B | 0.00 |
| 111 (YI) | China | $0.065B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.045B | 0.00 |
| HeartBeam (BEAT) | United States | $0.042B | 0.00 |
| Zhongchao (ZCMD) | China | $0.029B | 0.00 |
| Precipio (PRPO) | United States | $0.024B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.023B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.014B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.010B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.009B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.009B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.007B | 0.00 |
| Movano (MOVE) | United States | $0.005B | 0.00 |
| HeartSciences (HSCS) | United States | $0.005B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.004B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.003B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |